Investigating the impact of kefir in an inpatient setting
Research type
Research Study
Full title
Investigating the impact of kefir on Metabolic Syndrome subjects in an inpatient setting
IRAS ID
343900
Contact name
Isabel Garcia-Perez
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
3 years, 1 months, 21 days
Research summary
It is becoming increasingly apparent that the microorganisms in the human gut are pivotal to many aspects of our health. Disturbance of the gut microbiota has been linked to a variety of diseases, including colon cancer, diabetes, inflammatory bowel disease, and obesity. Consequently, gut microbiota has emerged as a potential target for the prevention or treatment of such diseases. Targeted manipulation of the gut microbiota can be achieved by dietary intervention, including using fermented foods, probiotics or prebiotics. The study intends to perform an extensive biogeographical analysis of digestive tract microbiome and of the metabolites within the intestinal space after the consumption of kefir from Metabolic Syndrome participants (MetS). This strategy is aiming at disentangling the metabolites coming from the kefir, those generated by the host and those by the gut microbiota because of the consumption of fermented food.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
26/LO/0235
Date of REC Opinion
7 May 2026
REC opinion
Further Information Favourable Opinion